Who Paid My Doc
A Phase 1, Open-Label, Randomized, Parallel Group, Single-Dose Clinica
Research payments
$9,167,437
Through program year 2024, $9,167,437 in research payments was reported against A Phase 1, Open-Label, Randomized, Parallel Group, Single-Dose Clinica, across 256 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,110,129 | 61 |
| 2023 | Research | $2,995,482 | 102 |
| 2022 | Research | $5,061,826 | 93 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Paul Pickrell Austin, TX Named on 20 payments
- Barbara Rizzardi West Jordan, UT Named on 19 payments
- Robert Lockwood Yukon, OK Named on 19 payments
- Jack Vu Long Beach, CA Named on 16 payments
- Muhammad Irfan Houston, TX Named on 16 payments
- Clint Flanagan Fort Collins, CO Named on 12 payments
- Margaret Chang Edgewater, FL Named on 10 payments
- David Halpert Lake Worth, FL Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.